Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

Treatment for advanced non-small cell lung cancer (NSCLC) has been significantly improved in recent years with the incorporation of drugs targeting antiangiogenesis and more specifically genomic alterations such as the EGFR mutations and ALK translocations. However, most patients invariably progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Moya-Horno, Irene, Viteri, Santiago, Karachaliou, Niki, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Special Collection: Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784559/
https://www.ncbi.nlm.nih.gov/pubmed/29383034
http://dx.doi.org/10.1177/1758834017745012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784559/
https://www.ncbi.nlm.nih.gov/pubmed/29383034
http://dx.doi.org/10.1177/1758834017745012

Ejemplares similares